&nbsp;

Drugs Used:

abemaciclib,

letrozole

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

SELP

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Funding:

Exceptional Access Program

selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)

Drugs Used:

selpercatinib

Quick Link(s):

Regimen Monograph

Apr 2025

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative

Funding:

New Drug Funding Program

Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia

Drugs Used:

blinatumomab

Quick Link(s):

Regimen Monograph

Oct 2024

Regimen

TECL; TECL(RAMP)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

teclistamab (Compassionate)

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

FOLFIRI+PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

NPAC+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

PERTuzumab,

trastuzumab,

nab-PACLitaxel (Unfunded with exceptions)

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Palliative

Funding:

New Drug Funding Program

Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

New Drug Funding Program

Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph- BCP-ALL)

Drugs Used:

blinatumomab

Quick Link(s):

Regimen Monograph

Oct 2024

Regimen

IDEL+RITU; IDEL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria

New Drug Funding Program

Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

idelalisib,

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

ABEMANAS

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

ODB - General Benefit

anastrozole

Drugs Used:

abemaciclib,

anastrozole

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

AFAT

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

AFAtinib - For first-line monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria

Drugs Used:

AFAtinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

DHAP

Cancer Type:

Hematologic,

Lymphoma - Hodgkin,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used: